PUT/NOVO-NORDISK B/400/0.1/20.09.24 | Real-time BOERSE MUENCHEN 01:56:28 04/07/2024 pm IST | ||
| 0.01 EUR | +11.11% |
|
| Current month | +125.00% | ||
| 1 month | +28.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 0.01 | +11.11% |
| 03/24/03 | 0.009 | 0.00% |
| 02/24/02 | 0.009 | +50.00% |
| 01/24/01 | 0.006 | +50.00% |
| 28/24/28 | 0.004 | -20.00% |
Real-time BOERSE MUENCHEN
Last update July 04, 2024 at 01:56 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GG12BH |
| ISIN | DE000GG12BH7 |
| Date issued | 13/12/2023 |
| Strike | 400 kr |
| Maturity | 20/09/2024 (79 Days) |
| Parity | 10 : 1 |
| Emission price | 0.1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.144 € |
|---|---|
| Lowest since issue | 0.003 € |
| Spread | 0.096 € |
| Spread % | 96.00% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
967.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-1.59%
- Stock Market
- Warrants
- Warrant
